Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Janne PA, Cichowski K
J Clin Invest. 2023 Aug 15;133(16):e167651. doi: 10.1172/JCI167651.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.